Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Opthea Limited

Opthea to Receive US$35M Commitment and Additional US$50M Funding
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea Receives A$8.8 million R&D Tax Incentive
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea to Present at the FLORetina 2023 Congress
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea to Present at the Jefferies 2023 London Healthcare Conference
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea to Participate at the 2023 Euretina Congress
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea to Present at the 2023 Ophthalmology Innovation Summit
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea Appoints Anshul Thakral as Non-Executive Director of the Board
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea to Present at the Jefferies 2023 Healthcare Conference
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea To Present at the JMP Securities Life Sciences Conference
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea Receives A$8.7 million R&D Tax Incentive
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare Conference
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea To Present at SVB Leerink Global Biopharma Conference
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea To Present at Sequire Biotechnology Conference
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea to Present at the FLORetina 2022 Congress
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea to Present at Jefferies London Healthcare Conference
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Opthea Expands Leadership Team with the Appointment of Timothy E. Morris as Chief Financial Officer
From Opthea Limited
Via GlobeNewswire
Tickers ASX:OPT OPT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.